Entero Healthcare Solutions Stock Price Today (NSE: ENTERO)
Fundamental Score
Entero Healthcare Solutions Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Entero Healthcare Solutions share price today is ₹1247.80, up +0.05% on NSE/BSE as of 30 March 2026. Entero Healthcare Solutions (ENTERO) is a Small-cap company in the Pharmacy Retail sector with a market capitalisation of ₹4.57K (Cr). The 52-week high for ENTERO share price is ₹1510.80 and the 52-week low is ₹944.00. At a P/E ratio of 41.31x, ENTERO is currently trading below its industry average P/E of 45.55x. The company has a Return on Equity (ROE) of 5.63% and a debt-to-equity ratio of 0.25.
Entero Healthcare Solutions Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Entero Healthcare Solutions Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Entero Healthcare Solutions Share Price: An ROCE Efficiency Analysis
One overlooked dynamic in the Pharmacy Retail industry is the increasing demand for specialized distribution networks capable of handling temperature-sensitive pharmaceuticals and delivering to smaller, independent pharmacies often underserved by larger players. This analysis examines the implications of Return on Capital Employed (ROCE) for Entero Healthcare Solutions share price, currently trading at ₹1140.699951. The company's Price-to-Earnings (PE) ratio stands at 41.31, while its ROCE is 8.71%. This raises pertinent questions about the firm's efficiency in deploying capital relative to its valuation.
A core element of fundamental analysis is assessing how efficiently a company utilizes its capital to generate profits. Entero's ROCE of 8.71% indicates the return generated from each rupee invested in the business. This figure must be viewed in the context of its PE ratio and compared to its sector peers. A high PE ratio coupled with a relatively modest ROCE may suggest the market anticipates significant future growth, or that the current valuation incorporates factors beyond current profitability.
Compared to
Medplus Health Services Ltd, a key aspect of evaluating Entero's future prospects lies in assessing management's strategic vision and execution capabilities. While quantifiable metrics like ROCE offer valuable insights, the quality of leadership in navigating the complex pharmaceutical distribution landscape is equally crucial. Differences in supply chain management, customer acquisition strategies, and inventory control, all influenced by management decisions, can significantly impact ROCE and long-term value creation.The 8.71% ROCE directly impacts the company's economic moat – its ability to sustain competitive advantages. A higher ROCE generally suggests a stronger moat. In Entero's case, a relatively lower ROCE might indicate a need to further optimize capital allocation, improve operational efficiency, or explore avenues for higher-margin revenue streams to strengthen its competitive position and improve long term shareholder value. Failure to improve ROCE might make the company more susceptible to competition and erode its ability to generate sustainable profits over time. This analysis is part of an 80-parameter fundamental audit verified by Sweta Mishra and is for observational purposes only.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Entero Healthcare Solutions Fundamental Analysis & Valuation Benchmarking
Educational evaluation of ENTERO across key market metrics for learning purposes.
Positive Indicators
7 factors identified
Robust Profit Growth (33.78%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (20.78%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (30.44% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Strong Profit Growth Track Record (151.54% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.25)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Balanced Promoter Holding (52.42%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
7 factors identified
Below-Average Return on Equity (5.63%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (8.71%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Margin Pressure Concerns (2.33%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges.
Premium Valuation Risk (P/E: 41.31x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Weak Earnings Growth (-25.34% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Negative Free Cash Flow (₹-302.73 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Entero Healthcare Solutions Financial Statements
Comprehensive financial data for Entero Healthcare Solutions including income statement, balance sheet and cash flow
About ENTERO (Entero Healthcare Solutions)
Entero Healthcare Solutions is a pioneering force reshaping the pharmaceutical distribution landscape in India. The company operates as a critical intermediary, connecting pharmace...utical manufacturers with a vast network of retail pharmacies, hospitals, and clinics. Entero distinguishes itself by providing a comprehensive suite of services that go beyond simple logistics. They facilitate efficient and timely delivery of a wide array of products, from essential medicines and life-saving drugs to cutting-edge therapies and specialized medical supplies. The company’s technology-driven platform optimizes inventory management, demand forecasting, and order fulfillment, ensuring that healthcare providers have access to the products they need, when they need them. By streamlining the supply chain and reducing complexities, Entero enables pharmacies and healthcare institutions to focus on patient care. Entero’s expansive product portfolio caters to diverse medical needs, encompassing everything from established pharmaceutical brands to innovative biosimilars and nutraceuticals. The company meticulously selects its product range, ensuring quality, efficacy, and alignment with prevailing healthcare standards. In addition to pharmaceuticals, Entero provides a range of surgical products, consumables, and medical devices. This comprehensive offering makes Entero a one-stop-shop for healthcare providers, simplifying procurement and reducing the burden of managing multiple suppliers. The commitment to providing a diverse and high-quality product selection underscores Entero's dedication to supporting the entire healthcare ecosystem. Furthermore, Entero Healthcare Solutions is more than just a distribution company; it is a knowledge partner and solutions provider. They actively support their retail partners with valuable data insights, marketing programs, and training initiatives. By leveraging data analytics and market research, Entero equips pharmacies with the tools they need to make informed decisions about inventory management, pricing strategies, and product promotion. Their commitment to fostering mutually beneficial partnerships extends beyond simple transactions, building trust and enabling sustained growth for both Entero and its network of healthcare providers. This dedication to innovation and customer centricity positions Entero as a leader in the evolving pharmaceutical distribution market.
Company Details
Key Leadership
ENTERO Share Price: Frequently Asked Questions
What is the current share price of Entero Healthcare Solutions (ENTERO)?
As of 30 Mar 2026, 12:03 pm IST, Entero Healthcare Solutions share price is ₹1247.80. The ENTERO stock has a market capitalisation of ₹4.57K (Cr) on NSE/BSE.
Is ENTERO share price Overvalued or Undervalued?
ENTERO share price is currently trading at a P/E ratio of 41.31x, compared to the industry average of 45.55x. Based on this relative valuation, the Entero Healthcare Solutions stock appears to be Undervalued against its sector peers.
What is the 52-week high and low of ENTERO share price?
The 52-week high of ENTERO share price is ₹1510.80 and the 52-week low is ₹944.00. These values are updated daily from NSE/BSE price data.
What factors affect the Entero Healthcare Solutions share price?
Key factors influencing ENTERO share price include quarterly earnings growth (Sales Growth: 20.78%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Entero Healthcare Solutions a good stock for long-term investment?
Entero Healthcare Solutions shows a 5-year Profit Growth of 151.54% and an ROE of 5.63%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.25 before investing in ENTERO shares.
How does Entero Healthcare Solutions compare with its industry peers?
Entero Healthcare Solutions competes with major peers in the Pharmacy Retail. Investors should compare ENTERO share price P/E of 41.31x and ROE of 5.63% against the industry averages to determine competitive standing.
What is the P/E ratio of ENTERO and what does it mean?
ENTERO share price has a P/E ratio of 41.31x compared to the industry average of 45.55x. Investors pay ₹41 for every ₹1 of annual earnings.
How is ENTERO performing according to Bull Run's analysis?
ENTERO has a Bull Run fundamental score of 56.9/100, indicating moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does ENTERO belong to?
ENTERO operates in the Pharmacy Retail industry. This classification helps understand the competitive landscape and sector-specific trends affecting Entero Healthcare Solutions share price.
What is Return on Equity (ROE) and why is it important for ENTERO?
ENTERO has an ROE of 5.63%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Entero Healthcare Solutions generates profits from shareholders capital.
How is ENTERO debt-to-equity ratio and what does it indicate?
ENTERO has a debt-to-equity ratio of 0.25, which indicates conservative financing with low financial risk.
What is ENTERO dividend yield and is it a good dividend stock?
ENTERO offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Entero Healthcare Solutions shares.
How has ENTERO share price grown over the past 5 years?
ENTERO has achieved 5-year growth rates of: Sales Growth 30.44%, Profit Growth 151.54%, and EPS Growth -25.34%.
What is the promoter holding in ENTERO and why does it matter?
Promoters hold 52.42% of ENTERO shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Entero Healthcare Solutions.
What is ENTERO market capitalisation category?
ENTERO has a market capitalisation of ₹4566 crores, placing it in the Small-cap category.
How volatile is ENTERO stock?
ENTERO has a beta of N/A. A beta > 1 suggests the Entero Healthcare Solutions stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is ENTERO operating profit margin trend?
ENTERO has a 5-year average Operating Profit Margin (OPM) of 2.33%, indicating the company's operational efficiency.
How is ENTERO quarterly performance?
Recent quarterly performance shows Entero Healthcare Solutions YoY Sales Growth of 20.78% and YoY Profit Growth of 33.78%.
What is the institutional holding pattern in ENTERO?
ENTERO has FII holding of 14.68% and DII holding of 9.64%. Significant institutional holding often suggests professional confidence in the Entero Healthcare Solutions stock.